This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
by Zacks Equity Research
Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.
Top Ranked Growth Stocks to Buy for June 23rd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 23rd
The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bet on These 5 High Earnings Yield Stocks to Book Profits
by Zacks Equity Research
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.
Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay
by Kinjel Shah
Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.
Roche's Tecentriq With Chemotherapy Meets Goal for TNBC
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy meets goal in early TNBC patients.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - June 18, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Top Research Reports for Netflix, Bristol-Myers & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY) and NextEra Energy (NEE).
Bristol-Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $56.95 in the latest trading session, marking a -0.19% move from the prior day.
Zacks.com featured highlights include: Big Lots, Dollar General, Kroger and Bristol-Myers
by Zacks Equity Research
Zacks.com featured highlights include: Big Lots, Dollar General, Kroger and Bristol-Myers
Easy Investing Secrets to an Early Retirement - June 16, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
3 Reasons Growth Investors Will Love Bristol-Myers (BMY)
by Zacks Equity Research
Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Grab 4 Solid Dividend Growth Stocks at a Bargain Price
by Sweta Killa
Dividend-paying securities are a major source of consistent income for investors to create wealth when returns from the equity market are at risk.
Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Signs That Your Trading Will Ruin Your Retirement - June 12, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
Mismatch in Main Street & Wall Street? 4 Quality Picks
by Sanghamitra Saha
With rising uncertainty and a global recessionary environment, investors may consider parking money in quality stocks.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - June 12, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.
AbbVie Inks Deal With Genmab, Announces ADC Candidate Data
by Zacks Equity Research
AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
by Zacks Equity Research
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.